Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 3
2012 1
2016 1
2017 1
2018 1
2019 1
2022 5
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
Specific Mutations in Aph1 Cause γ-Secretase Activation.
Watanabe H, Yoshida C, Hidaka M, Ogawa T, Tomita T, Futai E. Watanabe H, et al. Among authors: yoshida c. Int J Mol Sci. 2022 Jan 3;23(1):507. doi: 10.3390/ijms23010507. Int J Mol Sci. 2022. PMID: 35008932 Free PMC article.
Initiation of renin-angiotensin system inhibitors and first complete remission in patients with primary nephrotic syndrome: a nationwide cohort study.
Shimizu S, Niihata K, Nishiwaki H, Shibagaki Y, Yamamoto R, Nitta K, Tsukamoto T, Uchida S, Takeda A, Okada H, Narita I, Isaka Y, Kurita N; Japan Nephrotic Syndrome Cohort Study Group. Shimizu S, et al. Clin Exp Nephrol. 2023 May;27(5):480-489. doi: 10.1007/s10157-023-02331-3. Epub 2023 Feb 25. Clin Exp Nephrol. 2023. PMID: 36840902
Predictors of early remission of proteinuria in adult patients with minimal change disease: a retrospective cohort study.
Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Takeda A, Uchida S, Tsukamoto T, Tsuruya K, Akai Y, Nitta K, Fukunaga M, Hayashi H, Masutani K, Wada T, Konta T, Katafuchi R, Nishio S, Goto S, Tamai H, Shirasaki A, Shoji T, Nagai K, Nishino T, Yamagata K, Kazama JJ, Hiromura K, Yasuda H, Mizutani M, Naruse T, Hiramatsu T, Morozumi K, Sobajima H, Saka Y, Ishimura E, Ichikawa D, Shigematsu T, Sofue T, Fujimoto S, Ito T, Sato H, Narita I, Isaka Y; JNSCS Investigators. Yamamoto R, et al. Sci Rep. 2022 Jun 13;12(1):9782. doi: 10.1038/s41598-022-13067-7. Sci Rep. 2022. PMID: 35697724 Free PMC article.
Time to remission of proteinuria and incidence of relapse in patients with steroid-sensitive minimal change disease and focal segmental glomerulosclerosis: the Japan Nephrotic Syndrome Cohort Study.
Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Takeda A, Tsukamoto T, Uchida S, Tsuruya K, Shoji T, Hayashi H, Akai Y, Fukunaga M, Konta T, Nishio S, Goto S, Tamai H, Nagai K, Katafuchi R, Masutani K, Wada T, Nishino T, Shirasaki A, Sobajima H, Nitta K, Yamagata K, Kazama JJ, Hiromura K, Yasuda H, Mizutani M, Akahori T, Naruse T, Hiramatsu T, Morozumi K, Mimura T, Saka Y, Ishimura E, Hasegawa H, Ichikawa D, Shigematsu T, Sato H, Narita I, Isaka Y; Japan Nephrotic Syndrome Cohort Study investigators. Yamamoto R, et al. J Nephrol. 2022 May;35(4):1135-1144. doi: 10.1007/s40620-022-01279-z. Epub 2022 Apr 2. J Nephrol. 2022. PMID: 35366214
16 results